- Nachrichtendetail
-
15.07.2024 07:30:28 - dpa-AFX: EQS-News: Sales growth Q2/2024 +14 % and H1/2024 +10 % compared to previous year; positive development in all operating areas (english)
Sales growth Q2/2024 +14 % and H1/2024 +10 % compared to previous year;
positive development in all operating areas
EQS-News: aap Implantate AG / Key word(s): Quarterly / Interim
Statement/Preliminary Results
Sales growth Q2/2024 +14 % and H1/2024 +10 % compared to previous year;
positive development in all operating areas
15.07.2024 / 07:30 CET/CEST
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
* Sales: H1/2024 increased by 10% to EUR 6.4 million compared to H1/2023;
aap Implantate AG ("aap" or "Company") continued its growth in the second
quarter. In the EMEA region, aap was able to significantly increase the
overall result for the first half of the year, mainly due to an order from
an aid organization in the second quarter. At the same time, existing
markets such as Spain/Portugal (+41% yoy), South Africa (+9% yoy) and
smaller countries in the Middle East achieved up to double-digit growth
rates.
The effects of the reorganization in the USA, which were highlighted in the
first quarter, could not be offset in the second quarter, meaning that sales
were down 22% on the previous year in the first half of the year. Positive
developments in customer acquisition as well as a well-filled project
pipeline make the Management Board confident that this decline can be made
up for over the course of the year through the continued focused work of the
reorganized and growing team.
In Latin America, after a strong first quarter, which was primarily
characterized by investments in aap systems to equip new customers, growth
continued in the second quarter. In addition to Brazil (+67% yoy) and Mexico
(+23% yoy), aap's largest sales markets, other markets such as Colombia
(+39% yoy) also grew in terms of sales. In the APAC region, the customer
base was expanded to include new customers, meaning that further future
growth is expected in the region.
Q2/2024 - Turnover
Half-year 2024 - Turnover
The company is making great progress in the ongoing human clinical trial
with the antibacterial implant technology and has recruited 200 patients to
date. Due to the continued very positive progress of the study, aap applied
to the approving body to be able to complete patient recruitment in
mid-2024. If approved, the 12-month follow-up phase with the last patient
included could be completed earlier than originally planned.
At the beginning of July, aap received the positive news that the first
hurdle in the application for funding and investment under the European
Horizon program (EIC Accelerator) had been successfully overcome and that
the company could submit a full application for its antibacterial implant
technology in a further step. A positive assessment of the full application
would open the possibility that the European Investment Bank could invest in
aap in 2025 and provide significant support for the investments required for
the transformation.
The German Federal Ministry of Education and Research ("BMBF") is funding
the clinical study. The grant awarded to the company (funding codes
13GW0313A+B, 13GW0449A+B) is part of the BMBF's "Healthcare industry in the
healthcare research framework program" (= funding body). According to the
BMBF, funding is provided for projects on the topic of "Transferring medical
technology solutions to patient care - proving clinical evidence without
delay". For further information, please refer to the relevant guidelines on
the BMBF website: https://www.bmbf.de/foerderungen/bekanntmachung-1376.html.
The company also made significant progress towards MDR approval. In the
first few months, all main product files required for the MDR were submitted
to the notified body. A first main product file was positively reviewed by
the notified body in accordance with the MDR at the end of June. The company
remains committed to its plan to complete MDR approval by the end of 2024
and thus launch new products on the CE market in 2025.
As part of aap's further product development activities, the company also
received US FDA approval for its double-threaded compression screws in the
first half of the year and can begin preparations for market launch
activities in the United States and other markets that accept FDA approval
for 2025 in the second half of the year.
The detailed half-year report will be published on August 14, 2024.
---------------------------------------------------------------------------------------------------
aap Implantate AG (ISIN DE0005066609) - General Standard/Regulated Market -
All German stock exchanges -
About aap Implantate AG
aap Implantate AG is a globally active medical technology company based in
Berlin, Germany. The company develops, produces and markets products for
traumatology. The IP-protected portfolio includes the innovative anatomical
plate system LOQTEQ® and a wide range of cannulated screws. In addition, aap
Implantate AG has an innovation pipeline with promising development projects
such as antibacterial silver coating technology and magnesium-based
implants. These technologies address critical problems in traumatology that
have not yet been adequately solved. In Germany, aap Implantate AG sells its
products directly to hospitals, purchasing groups and group clinics, while
internationally it primarily uses a broad network of distributors in around
25 countries. In the United States, the company relies on a sales strategy
via distribution agents through its subsidiary aap Implants Inc. The aap
Implantate AG share is listed in the General Standard of the Frankfurt Stock
Exchange (XETRA: AAQ.DE). For further information, please visit our website
at www.aap.de.
The figures presented in this press release may be subject to technical
rounding differences that do not affect the overall picture.
Forward-looking statements
This release may contain forward-looking statements that are based on the
current expectations, assumptions and forecasts of the Executive Board and
information currently available to it. The forward-looking statements are
not to be understood as guarantees of the future developments and results
mentioned therein. Various known and unknown risks, uncertainties and other
factors could lead to material differences between the actual results,
financial situation, development or performance of the company and the
estimates given here. These factors include those that aap has described in
published reports. Forward-looking statements therefore speak only as of the
date on which they are made. We assume no obligation to update the
forward-looking statements made in this release or to conform them to future
events or developments.
If you have any questions, please contact: aap Implantate AG; Rubino Di
Girolamo, Chairman of the Management Board/ CEO, Lorenzweg 5; 12099 Berlin
Phone: +49 (0)30 75019 - 170; Fax: +49 (0)30 75019 - 290; Email:
r.digirolamo@aap.de
---------------------------------------------------------------------------
15.07.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS
News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The EQS Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com
---------------------------------------------------------------------------
End of News EQS News Service
---------------------------------------------------------------------------
1945717 15.07.2024 CET/CEST
positive development in all operating areas
EQS-News: aap Implantate AG / Key word(s): Quarterly / Interim
Statement/Preliminary Results
Sales growth Q2/2024 +14 % and H1/2024 +10 % compared to previous year;
positive development in all operating areas
15.07.2024 / 07:30 CET/CEST
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
* Sales: Q2 at EUR 3.3 million (+14% yoy), main growth driver EMEA (Q2:
+44%);
* Sales: H1/2024 increased by 10% to EUR 6.4 million compared to H1/2023;
* The human clinical trial of the innovative antibacterial implant
technology has so far recruited 200 patients, and aap has applied to
complete patient recruitment;
aap Implantate AG ("aap" or "Company") continued its growth in the second
quarter. In the EMEA region, aap was able to significantly increase the
overall result for the first half of the year, mainly due to an order from
an aid organization in the second quarter. At the same time, existing
markets such as Spain/Portugal (+41% yoy), South Africa (+9% yoy) and
smaller countries in the Middle East achieved up to double-digit growth
rates.
The effects of the reorganization in the USA, which were highlighted in the
first quarter, could not be offset in the second quarter, meaning that sales
were down 22% on the previous year in the first half of the year. Positive
developments in customer acquisition as well as a well-filled project
pipeline make the Management Board confident that this decline can be made
up for over the course of the year through the continued focused work of the
reorganized and growing team.
In Latin America, after a strong first quarter, which was primarily
characterized by investments in aap systems to equip new customers, growth
continued in the second quarter. In addition to Brazil (+67% yoy) and Mexico
(+23% yoy), aap's largest sales markets, other markets such as Colombia
(+39% yoy) also grew in terms of sales. In the APAC region, the customer
base was expanded to include new customers, meaning that further future
growth is expected in the region.
Q2/2024 - Turnover
Turnover in TEUR Q2/2024 Q2/2023 Change
EMEA (= Europe, Middle East, Africa) 1.907 1.328 44%
North America (=USA) 683 937 -27%
LATAM (= Latin America) 639 564 13%
APAC (= Asia-Pacific) 102 80 27%
Turnover 3.330 2.909 14%
Half-year 2024 - Turnover
Turnover in TEUR 1.1.-30.6.202- 1.1.-30.6.202- Chang-
4 3 e
EMEA (= Europe, Middle East, 3.334 2.861 17%
Africa)
North America (=USA) 1.429 1.834 -22%
LATAM (= Latin America) 1.427 1.045 37%
APAC (= Asia-Pacific) 250 126 98%
Turnover 6.440 5.866 10%
The company is making great progress in the ongoing human clinical trial
with the antibacterial implant technology and has recruited 200 patients to
date. Due to the continued very positive progress of the study, aap applied
to the approving body to be able to complete patient recruitment in
mid-2024. If approved, the 12-month follow-up phase with the last patient
included could be completed earlier than originally planned.
At the beginning of July, aap received the positive news that the first
hurdle in the application for funding and investment under the European
Horizon program (EIC Accelerator) had been successfully overcome and that
the company could submit a full application for its antibacterial implant
technology in a further step. A positive assessment of the full application
would open the possibility that the European Investment Bank could invest in
aap in 2025 and provide significant support for the investments required for
the transformation.
The German Federal Ministry of Education and Research ("BMBF") is funding
the clinical study. The grant awarded to the company (funding codes
13GW0313A+B, 13GW0449A+B) is part of the BMBF's "Healthcare industry in the
healthcare research framework program" (= funding body). According to the
BMBF, funding is provided for projects on the topic of "Transferring medical
technology solutions to patient care - proving clinical evidence without
delay". For further information, please refer to the relevant guidelines on
the BMBF website: https://www.bmbf.de/foerderungen/bekanntmachung-1376.html.
The company also made significant progress towards MDR approval. In the
first few months, all main product files required for the MDR were submitted
to the notified body. A first main product file was positively reviewed by
the notified body in accordance with the MDR at the end of June. The company
remains committed to its plan to complete MDR approval by the end of 2024
and thus launch new products on the CE market in 2025.
As part of aap's further product development activities, the company also
received US FDA approval for its double-threaded compression screws in the
first half of the year and can begin preparations for market launch
activities in the United States and other markets that accept FDA approval
for 2025 in the second half of the year.
The detailed half-year report will be published on August 14, 2024.
---------------------------------------------------------------------------------------------------
aap Implantate AG (ISIN DE0005066609) - General Standard/Regulated Market -
All German stock exchanges -
About aap Implantate AG
aap Implantate AG is a globally active medical technology company based in
Berlin, Germany. The company develops, produces and markets products for
traumatology. The IP-protected portfolio includes the innovative anatomical
plate system LOQTEQ® and a wide range of cannulated screws. In addition, aap
Implantate AG has an innovation pipeline with promising development projects
such as antibacterial silver coating technology and magnesium-based
implants. These technologies address critical problems in traumatology that
have not yet been adequately solved. In Germany, aap Implantate AG sells its
products directly to hospitals, purchasing groups and group clinics, while
internationally it primarily uses a broad network of distributors in around
25 countries. In the United States, the company relies on a sales strategy
via distribution agents through its subsidiary aap Implants Inc. The aap
Implantate AG share is listed in the General Standard of the Frankfurt Stock
Exchange (XETRA: AAQ.DE). For further information, please visit our website
at www.aap.de.
The figures presented in this press release may be subject to technical
rounding differences that do not affect the overall picture.
Forward-looking statements
This release may contain forward-looking statements that are based on the
current expectations, assumptions and forecasts of the Executive Board and
information currently available to it. The forward-looking statements are
not to be understood as guarantees of the future developments and results
mentioned therein. Various known and unknown risks, uncertainties and other
factors could lead to material differences between the actual results,
financial situation, development or performance of the company and the
estimates given here. These factors include those that aap has described in
published reports. Forward-looking statements therefore speak only as of the
date on which they are made. We assume no obligation to update the
forward-looking statements made in this release or to conform them to future
events or developments.
If you have any questions, please contact: aap Implantate AG; Rubino Di
Girolamo, Chairman of the Management Board/ CEO, Lorenzweg 5; 12099 Berlin
Phone: +49 (0)30 75019 - 170; Fax: +49 (0)30 75019 - 290; Email:
r.digirolamo@aap.de
---------------------------------------------------------------------------
15.07.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS
News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The EQS Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com
---------------------------------------------------------------------------
Language: English
Company: aap Implantate AG
Lorenzweg 5
12099 Berlin
Germany
Phone: +49 (0) 30 75 019-0
Fax: +49 (0) 30 75 019-111
E-mail: info@aap.de
Internet: www.aap.de
ISIN: DE000A3H2101
WKN: A3H210
Listed: Regulated Market in Frankfurt (General Standard);
Regulated Unofficial Market in Berlin, Dusseldorf,
Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1945717
End of News EQS News Service
---------------------------------------------------------------------------
1945717 15.07.2024 CET/CEST
| Name | WKN | Börse | Kurs | Datum/Zeit | Diff. | Diff. % | Geld | Brief | Erster | Schluss | |
|---|---|---|---|---|---|---|---|---|---|---|---|
 |
AAP IMPLANTATE AG O.N. | A3H210 | Frankfurt | 1,130 | 16.08.24 08:00:32 | +0,040 | +3,67% | 0,000 | 0,000 | 1,130 | 1,130 |
